Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

44%

4 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 3

4(44.4%)

Early Phase 1

2(22.2%)

Phase 1

2(22.2%)

Phase 2

1(11.1%)

9Total

Phase 3(4)

Early Phase 1(2)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT05500586Phase 1Completed

The Effects of Glucagon on Hepatic Metabolism

Role: lead

NCT04466566Phase 3Completed

A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

Role: lead

NCT05499702Phase 2Recruiting

The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

Role: lead

NCT04466618Phase 3Completed

Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes

Role: lead

NCT04459338Phase 3Completed

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

Role: lead

NCT04461015Phase 3Completed

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans

Role: lead

NCT01843881Early Phase 1Completed

The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass

Role: lead

NCT01843855Early Phase 1Completed

The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

Role: lead

NCT01218633Phase 1Completed

Dose-response Study of Exendin-9,39 on Glucose Metabolism

Role: lead

All 9 trials loaded